Sensa Core Attracts PE Funds for Controlling Stake in Medical Device

Summary:
Sense Core Medical Device has attracted strong interest from private equity giants such as KKR, TPG, Kedara Capital and has attracted qualities for a controlled stake. The potential deal can give the company about $ 300 million (2,600 crore) prices. With growing product portfolio and frequent financial performance, Sense Core is seen as a strong player in India’s expanded Medtech market. 

Strong financials and product portfolio 

Founded in 2006 by Dr. Ravi K. Meruva, Sense Core has become one of the largest manufacturers in India’s in vitro diagnostic (IVD) analyzer and care testing devices. Its portfolio includes blood gas analyzer, electrolyte system, glucose meter, lactate meter, hemoglobin meter and cholesterol meter. Additionally, the firm provides maintenance and support services for electrolyte analyzers of other brands, strengthening its position in India’s diagnostics ecosystem.  

In the financial year 2024-25, Sensa Core generated estimated revenue of around ₹ 400crore, with EBITDA, with the EBITDA, the earlier filing reported a revenue of ₹ 320crore by the earlier filing earlier before the first ₹ 80-100 crore, in which the year’s growth was confirmed on the growth of the year. 

PE drivers: market, scale and trusted distribution 

Private equity funds have focused on India’s medtech region rapidly due to reliable development and flexible margin. A PE Fund manager quoted in the media said that “once a strong distribution network occurs in place and confidence is established with doctors, companies in this space generate stable, estimated revenue.” Indian device manufacturers are now seen “equal to global players in terms of quality” 

The comprehensive Indian Medtech market is estimated to be almost quadruple around the USD50billion by 2030, the investor optimism is well to benefit in the structural expansion of the region to fuel the low-cost production of the optimism sense core, diverse product range, and fueling relations with hospitals and clinical centers. 

Deal advisors and comments 

Ved corporate advisors are reported to advise promoters on possible transactions. While the specific deal structure or time has not been disclosed, non-intelligent dialects are expected within the coming month.  

Nagaraju Meruva, Executive Director of Sense Core, has called the information “baseless” and refused to comment. Representatives of KKR, TPG, Kedara and Multiples have refused to offer any public statement to date. 

A rising tide in medtech investment 

This interest follows the recent striking of activity in the region. Abu Dhabi Investment Authority (Adia) invested USD200million for minority stake in Micro Life Sciences (Meril), which led to its evaluation to usD6.6billion. Meanwhile, KKR acquired Healthium Medtech (East India) last year. ₹ 7,000 crore. 

Potential entry of sense core in PE Space Signal increases confidence in the form of investment opportunities in domestic meditech businesses, especially with proven performance, strong technical abilities and ability to expand rapidly in export -powered development. 

Disclaimer:   

(The views expressed are solely on the basis of research. Indiagnostic shall not be responsible for any damage caused to any person/organization directly or indirectly).